Anuh Pharma Ltd
Anuh Pharma Q2 FY25: Revenue ₹169.35 Cr
Q2 FY25 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹166Cr
- +10.7% YoY
- Net profit
- ₹15Cr
- +7.1% YoY
- Margin
- 10%
- −2 pp YoY
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Anuh Pharma Ltd's Q2 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY25 Revenue: Rs 169.35 Cr (Page 6). EBITDA for Q2 FY25: Rs. 20.28 Cr, a 41.93% increase QoQ but a 7.95% decrease YoY (Q2 FY24: Rs. 21.98 Cr approx. derived).
From Anuh Pharma Ltd's Q2 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q2 FY25 Revenue: Rs 169.35 Cr (Page 6)
- Q2 FY24 Revenue (implied from Q1 FY25): Rs 141.62 Cr (Page 6)
- Quarter-over-quarter growth: 20% (Page 6)
- H1 FY25 Operating Revenue: Rs 303.86 Cr vs. Rs 311.01 Cr in H1 FY24, a -2.30% YoY decline (Page 13)
- Capacity expansion from 1800 MTPA to 2200 MTPA (Page 6)
2 more points from Anuh Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capital expenditure of Rs. 20 Crore made to expand capacity at the current location (Page 6).
- Capacity increased from 1800 MTPA to 2200 MTPA as a result of this capex (Page 6).
- Increased capacity was made ready for commercialization by mid-November 2024 (Page 6).
- Manufacturing capacity at L&L site enhanced to 12 MTPA specifically for Corticosteroids to increase market share (Page 29).
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Anuh Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Anuh Pharma Ltd — Quarterly revenue & net profit
Anuh Pharma Ltd Q2 FY25 results — key figures
| ₹ Cr | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 166 | 150 | +10.7% | 138 | +20.3% |
| Operating profit (EBITDA) | 17 | 18 | -5.6% | 11 | +54.5% |
| Operating margin | 10% | 12% | -2 pp | 8% | +2 pp |
| Profit before tax | 18 | 18 | 0% | 12 | +50% |
| Net profit (PAT) | 15 | 14 | +7.1% | 10 | +50% |
| EPS (₹) | 1.50 | 1.38 | +8.7% | 0.95 | +57.9% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹185 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Jubilant Pharmo (Q2 FY25)
Q2’FY25 total income grew 5% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
- Wockhardt (Q2 FY25)
Q1 FY25 total income reported at INR 747 Cr., a 14% growth year-on-year versus Q1 FY24 income of INR 658 Cr. Key concall takeaways from Wockhardt Ltd's Q2 FY25…
- Themis Medicare (Q2 FY25)
117.01 Cr, up 11.67% YoY from Rs. Key concall takeaways from Themis Medicare Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Anuh Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Anuh Pharma Ltd Q2 FY25 results?
Q2 FY25 Revenue: Rs 169.35 Cr (Page 6). EBITDA for Q2 FY25: Rs. 20.28 Cr, a 41.93% increase QoQ but a 7.95% decrease YoY (Q2 FY24: Rs. 21.98 Cr approx. derived).
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anuh Pharma Ltd planning capital expenditure?
Capital expenditure of Rs. 20 Crore made to expand capacity at the current location (Page 6).
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.